Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $46.57 -0.18 (-0.39%) 8:10 AM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $46.57 -0.18 (-0.39%) 8:10 AM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum F VGM
Zacks News
Corcept Therapeutics Focuses on Korlym's Label Expansion
by Zacks Equity Research
We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.
Why is Corcept's Stock Up More Than 60% So Far This Year?
by Zacks Equity Research
Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
by Zacks Equity Research
Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
by Zacks Equity Research
The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.
AMAG Files for FDA Approval of Subcutaneous Form of Makena
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.
Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Strives to Commercialize Key Drug Korlym
by Zacks Equity Research
We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.
Corcept Korlym Positive in Phase I/II Breast Cancer Study
by Zacks Equity Research
Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.
New Strong Buy Stocks for September 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include ARCO, CORT, EXEL, HL and LXP.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Bear of the Day: Jazz Pharma (JAZZ)
by David Bartosiak
A little less JAZZ and a lot more blues has been playing lately